Clinical Trials Logo

DNA Double Strand Break clinical trials

View clinical trials related to DNA Double Strand Break.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03652142 Recruiting - HNSCC Clinical Trials

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Start date: May 1, 2018
Phase:
Study type: Observational

Nivolumab is FDA-approved for the treatment of patients with recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). HNSCC whose disease has progressed within 6 months after platinum-based chemotherapy. The development of predictive biomarkers is needed to optimize patient benefit, minimize risk of toxicities and guide combination strategies.